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Enterobacterial strains resistant to polymyxins are being increasingly reported worldwide. The conventional methods for detec-
tion of colistin-resistant isolates such as broth microdilution remain time-consuming (24 to 48 h), andmethods such as disc dif-
fusion and Etest are not reliable. Recently, the rapid polymyxin NP test was developed for rapid identification of polymyxin-re-
sistant Enterobacteriaceae. This test is based on the detection of glucose metabolism related to bacterial growth in the presence
of a defined concentration of colistin (or polymyxin B). The formation of acid metabolites is evidenced by a color change of a pH
indicator (red phenol) in less than 2 h. In this study, the polymyxin NP test was evaluated for detection of colistin-resistant En-
terobacteriaceae directly from blood cultures. The test was performed with 73 blood culture sets (either spiked or clinical blood
cultures) with various enterobacterial species. The test exhibited excellent discrimination between polymyxin-resistant and
polymyxin-susceptible enterobacterial isolates, and results are obtained from blood cultures within 4 h. It is easy to perform and
requires neither subculture nor a centrifugation step. This test is rapid, specific, and sensitive and allows early identification of
polymyxin-resistant Enterobacteriaceae directly from blood cultures.
The spread of carbapenemase-producing Enterobacteriaceae hasnow been reported worldwide (1). Considering the paucity of
antibiotics that are effective against thosemultidrug-resistant bac-
teria, it is of utmost importance to preserve the clinical efficacy of
last-resort antibiotics such as polymyxins (colistin and polymyxin
B) (2).However, polymyxin-resistantEnterobacteriaceae are being
increasingly reported worldwide, exhibiting either chromosomal
mutations (3) or plasmid-mediated mcr-1 gene acquisition (4).
The methods available to determine polymyxin susceptibility re-
quire isolation and growth of the bacteria from the infected sam-
ples, and the susceptibility testing methods add, at least, an addi-
tional delay of 18 h to obtain the results (5). Moreover, routine
methods used in the clinical microbiology laboratory (disk diffu-
sion, Etest strips, and some automated systems such as the Vitek2
and the MicroScan) are not reliable for detecting polymyxin-re-
sistant isolates (5–9). Molecular tests are not effective for deter-
mining polymyxin resistance due to the variety of genes that may
be altered or truncated as a source of chromosomal resistance (3).
Rapid identification and antimicrobial susceptibility testing
are essential for guiding clinicians in the selection of the most
appropriate treatment for patients with bloodstream infections.
The mortality rates from sepsis in intensive care units range from
20 to 60% worldwide. Inappropriate initial antimicrobial therapy
for septic shock occurs in about 20%of patients, is associated with
a 5-fold reduction in survival (10), and is responsible for an in-
creased length of hospital stay (11). This is largely due to the fact
that its takes several days to obtain the susceptibility pattern of the
bacteria responsible for the septicemia. In Italy, a large hospital
outbreak of colistin-resistant and carbapenemase (KPC)-produc-
ing Klebsiella pneumoniae isolates, correlating with the local in-
creased colistin consumption, has been recently described (12).
Therefore, there is a need for a rapid detection of polymyxin-
resistant isolates from blood cultures.
Recently, a diagnostic test (the rapid polymyxin NP test) based
on the detection of glucosemetabolism related to bacterial growth
in the presence of colistin has been developed to rapidly identify
(2 h) polymyxin-resistant enterobacterial strains from colonies
grown on solid media (13). This test yields sensitivity and speci-
ficity values of 99.3% and 95.4%, respectively. It has not yet been
evaluated with clinical samples.
The aim of this study was to determine the ability of the rapid
polymyxin NP test to detect polymyxin-resistant Enterobacteria-
ceae from blood cultures. First, we evaluated this test with blood
cultures spiked with colistin-resistant enterobacterial strains ex-
hibiting various mechanisms of resistance (intrinsic or acquired,
chromosomal, and plasmid-mediated). Then, the test was per-
formedprospectively on clinical blood cultures positive forGram-
negative bacteria.
MATERIALS AND METHODS
Spiked blood cultures. The panel of strains used for spiking blood cul-
tures included a single reference strain susceptible to colistin (Escherichia
coli ATCC 25922) and 52 colistin-resistant enterobacterial strains (MICs
of colistin ranging from 4 to 128 g/ml). Among the latter strains, 5
strains exhibited an intrinsic polymyxin resistance trait (Proteus spp., n
2; Providencia spp., n 1;Morganella spp., n 1; and Serratia spp., n
1), and 47 strains presented an acquired resistance trait and belonged to
various species (E. coli, n 11; Klebsiella spp., n 31; Enterobacter spp.,
n 4; and Hafnia alvei, n 1). Some of the strains had previously been
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TABLE 1 Rapid polymyxin NP test results for spiked blood cultures and clinical blood cultures
Strain Species Origin Phenotypea
Mechanism of resistance
to colistin
MIC for
colistinb
Rapid polymyxin NP testc
Aerobic vial Anaerobic vial
Clinical blood cultures
B1 Escherichia coli France S NAd 0.12  (4 h)  (4 h)
B2 Escherichia coli France S NA 0.12  (4 h)  (4 h)
B3 Escherichia coli France S NA 0.12  (4 h)  (4 h)
B4 Escherichia coli France S NA 0.12  (4 h)  (4 h)
B5 Escherichia coli France S NA 0.25  (4 h)  (4 h)
B6 Escherichia coli France S NA 0.5  (4 h)  (4 h)
B7 Escherichia coli France S NA 0.12  (4 h)  (4 h)
B8 Klebsiella pneumoniae France S NA 0.12  (4 h)  (4 h)
B9 Klebsiella pneumoniae France S NA 0.12  (4 h)  (4 h)
B10 Klebsiella pneumoniae France S NA 0.12  (4 h)  (4 h)
B11 Klebsiella pneumoniae France S NA 0.25  (4 h)  (4 h)
B12 Klebsiella oxytoca France S NA 0.12  (4 h)  (4 h)
B13 Enterobacter cloacae France S NA 0.25  (4 h)  (4 h)
B14 Enterobacter cloacae France S NA 0.5  (4 h)  (4 h)
B15 Citrobacter koseri France S NA 0.12  (4 h)  (4 h)
B16 Citrobacter koseri France S NA 0.12  (4 h)  (4 h)
B17 Hafnia alvei France R Unknown 16  (3 h)  (3 h)
B18 Serratia marcescens France R Intrinsic 128  (2 h)  (3 h)
B19 Serratia marcescens France R Intrinsic 128  (2 h)  (3 h)
B20 Proteus vulgaris France R Intrinsic 128  (2 h)  (2 h)
Spiked blood cultures
FR-136 Escherichia coli ATCC 25922 S NA 0.25  (4 h)  (4 h)
FR-119 Escherichia coli France R Unknown 8  (4 h)  (4 h)
FR-120 Escherichia coli France R Unknown 16  (3 h)  (3 h)
FR-121 Escherichia coli France R Unknown 4  (3 h)  (2 h)
B21 Escherichia coli France R PmrB D152V 8  (4 h)  (4 h)
FR-93 Escherichia coli Switzerland R MCR-1 plasmid 4  (4 h)  (3 h)
FR-94 Escherichia coli South Africa R MCR-1 plasmid 8  (3 h)  (3 h)
FR-95 Escherichia coli South Africa R MCR-1 plasmid 8  (4 h)  (3 h)
FR-96 Escherichia coli South Africa R MCR-1 plasmid 8  (3 h)  (3 h)
FR-97 Escherichia coli South Africa R MCR-1 plasmid 16  (3 h)  (3 h)
FR-98 Escherichia coli South Africa R MCR-1 plasmid 8  (2 h)  (2 h)
FR-99 Escherichia coli South Africa R MCR-1 plasmid 16  (4 h)  (3 h)
FR-100 Klebsiella pneumoniae France R Unknown 32  (3 h)  (4 h)
FR-101 Klebsiella pneumoniae France R Unknown 64  (3 h)  (3 h)
FR-103 Klebsiella pneumoniae France R Unknown 4  (3 h)  (3 h)
FR-104 Klebsiella pneumoniae France R Unknown 64  (2 h)  (3 h)
FR-106 Klebsiella pneumoniae France R Unknown 128  (3 h)  (3 h)
FR-107 Klebsiella pneumoniae Spain R Unknown 32  (2 h)  (2 h)
FR-108 Klebsiella pneumoniae Spain R Unknown 32  (2 h)  (2 h)
FR-115 Klebsiella pneumoniae Colombia R Unknown 64  (3 h)  (3 h)
FR-118 Klebsiella pneumoniae Turkey R Unknown 4  (2 h)  (2 h)
FR-06 Klebsiella pneumoniae Colombia R PmrA G53C 64  (2 h)  (2 h)
FR-10 Klebsiella pneumoniae South Africa R PmrB T157P 16  (4 h)  (2 h)
FR-11 Klebsiella pneumoniae Colombia R PmrB T157P 32  (4 h)  (3 h)
FR-16b Klebsiella pneumoniae South Africa R PhoP D191Y 128  (3 h)  (3 h)
FR-21 Klebsiella pneumoniae France R MgrB N42Y et K43I 64  (3 h)  (3 h)
FR-22 Klebsiella pneumoniae Angola R MgrB I45T 64  (3 h)  (3 h)
FR-25 Klebsiella pneumoniae France R MgrB truncated 128  (4 h)  (2 h)
FR-32 Klebsiella pneumoniae Switzerland R MgrB truncated 64  (4 h)  (3 h)
FR-36 Klebsiella pneumoniae Colombia R MgrB truncated 64  (2 h)  (3 h)
FR-40 Klebsiella pneumoniae France R blaCTX-M-15/ISEcp1 into
mgrB gene
64  (2 h)  (2 h)
FR-42 Klebsiella pneumoniae France R IS102 intomgrB gene 128  (3 h)  (3 h)
FR-47 Klebsiella pneumoniae Turkey R IS903b intomgrB gene 64  (2 h)  (2 h)
FR-48 Klebsiella pneumoniae Spain R IS903 intomgrB gene 128  (3 h)  (3 h)
FR-49 Klebsiella pneumoniae France R IS5 intomgrB gene 64  (2 h)  (4 h)
FR-52 Klebsiella pneumoniae Turkey R IS5 intomgrB gene 128  (2 h)  (2 h)
(Continued on following page)
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characterized for their polymyxin resistancemechanisms at themolecular
level (13–19).
To spike the blood cultures, the colistin-resistant enterobacterial
strainswere subcultured onto Luria-Bertani agar overnight. Then, aerobic
and anaerobic blood culture vials without charcoal (BacT/Alert FA Plus
and BacT/Alert FN Plus, respectively; bioMérieux,Marcy l’Etoile, France)
containing 10ml of sterile humanbloodwere inoculatedwith 103CFU/ml
of the bacterial strain to be tested. This inoculumwas prepared by diluting
a 0.5 McFarland standard suspension (about 108 CFU/ml) in 0.9% NaCl.
Then, blood culture vials were incubated until a positive blood culturewas
detected by the BacT/Alert 3D blood culture system. With this protocol,
the time for detecting the positivity of the blood cultures ranged from 6 to
15 h, and the final inoculum ranged from107 to 109CFU/ml, as previously
reported (20).
Clinical blood cultures. All sets of positive blood cultures recovered
during the November 2015 to February 2016 period of time from nondu-
plicate patients that were detected as positive by the BacT/Alert 3D blood
culture system (bioMérieux) and stained as Gram-negative were in-
cluded. Both aerobic and anaerobic vials were tested. Species identifica-
tion was carried out with the matrix-assisted laser desorption ionization–
time of flight mass spectrometry (MALDI-TOF MS) Biotyper system
(Bruker Corporation, Bremen, Germany) after 3 h of incubation of the
blood culture on chocolate agar. Positive blood cultures with nonentero-
bacterial isolates or with a mix of bacteria were excluded from the testing.
Overall, a total of 20 monomicrobial blood cultures positive for entero-
bacterial isolates were tested (Table 1).
Colistin susceptibility testing.Colistin susceptibility testing was per-
formed by determination of MICs using the broth microdilution method
(BMD) according to the CLSI guidelines (21, 22). The BMDmethod was
carried out with colonies grown on chocolate agar after incubation of the
positive blood cultures. The EUCAST guidelines (version 2015)were used
for categorical agreement (23).
Detection of colistin resistance from positive blood cultures using
the rapid polymyxin NP test. For each positive blood culture tested
(spiked or clinical blood culture), 50 l of blood culture was mixed with
450 l of sterile 0.9% NaCl (10-fold dilution). The rapid polymyxin NP
test was then performed as described with bacterial colonies (13). Briefly,
50l of the 10-fold dilution of the blood culture wasmixedwith (i) 150l
of colistin-free polymyxin NP solution and (ii) 150 l of polymyxin NP
solution containing 5 g/ml of colistin sulfate (Sigma-Aldrich, Buchs,
Switzerland) in a 96-well polystyrene plate (reference no. 82.1582.001;
Sarstedt, Nümbrecht, Germany) (Fig. 1). The final concentration of colis-
tin was 3.75g/ml in each well. In parallel, 50l of 0.9%NaCl was mixed
with the polymyxinNP solution to verify the absence ofmedium contam-
ination. The plate was incubated at 35 2°C in ambient air for 4 h, and
visual inspection was performed each hour to observe the color change.
Test results were interpreted by technicians who were blinded to the sam-
ple identity. The test was considered negativewhen thewell containing the
mix with colistin remained orange and positive when it turned from or-
ange to yellow (Fig. 1). The test was considered noninterpretable when the
colistin-free well remained orange (absence of glucose metabolization)
(Fig. 1). E. coliATCC 25922 and aMorganellamorganii strain were used as
negative and positive controls, respectively.
RESULTS AND DISCUSSION
To determine the performance of the rapid polymyxin NP test
directly from blood cultures, 73 blood culture sets (aerobic and
anaerobic vials) positive for enterobacterial strains were tested,
including monomicrobial clinical samples and blood cultures
spiked with colistin-resistant isolates presenting various mecha-
nisms of resistance (intrinsic, acquired chromosomally encoded,
plasmid-mediated, and unknown mechanisms). The results for
the rapid polymyxin NP test were compared with theMICs deter-
mined by the BMD method taken as the gold standard.
The 52 blood cultures spiked with enterobacterial strains resis-
tant to colistin gave positive results in 2 to 4 h (Table 1), except for
a single colistin-resistant E. coli isolate that also gave a negative
result by using the rapid polymyxin NP test performed from col-
TABLE 1 (Continued)
Strain Species Origin Phenotypea
Mechanism of resistance
to colistin
MIC for
colistinb
Rapid polymyxin NP testc
Aerobic vial Anaerobic vial
FR-54 Klebsiella pneumoniae Colombia R ISKpn13 intomgrB gene 128  (2 h)  (3 h)
FR-56 Klebsiella pneumoniae Spain R ISKpn26 intomgrB gene 64  (2 h)  (2 h)
FR-68 Klebsiella pneumoniae Colombia R ISKpn14 intomgrB gene 32  (3 h)  (3 h)
FR-70 Klebsiella pneumoniae Colombia R IS10R intomgrB
promoter
128  (3 h)  (3 h)
FR-71 Klebsiella pneumoniae Turkey R ISKpn14 intomgrB
promoter
32  (2 h)  (2 h)
FR-89 Klebsiella pneumoniae Colombia R Deletion of 11 bp into
mgrB
128  (3 h)  (3 h)
FR-92 Klebsiella oxytoca Colombia R ISKpn26 intomgrB
promoter
64  (2 h)  (2 h)
FR-122 Enterobacter cloacae Colombia R Unknown 32  (3 h)  (3 h)
FR-123 Enterobacter cloacae Colombia R Unknown 128  (4 h)  (4 h)
FR-125 Enterobacter cloacae France R Unknown 128  (2 h)  (2 h)
FR-129 Enterobacter cloacae France R Unknown 32  (3 h)  (2 h)
FR-135 Hafnia alvei France R Unknown 16  (2 h)  (2 h)
FR-01 Morganella morganii France R Intrinsic 128  (2 h)  (2 h)
FR-02 Proteus mirabilis France R Intrinsic 128  (3 h)  (3 h)
FR-03 Proteus vulgaris France R Intrinsic 128  (3 h)  (2 h)
FR-04 Providencia stuartii France R Intrinsic 128  (2 h)  (3 h)
FR-05 Serratia marcescens France R Intrinsic 128  (3 h)  (3 h)
a S, susceptible; R, resistant.
b MIC values of colistin: the breakpoint value for susceptible is2 g/ml and for resistance is2 g/ml for Enterobacteriaceae according to the EUCAST (23).
c Discrepant results obtained with the rapid polymyxin NP test compared to the broth dilution method are in bold., negative;, positive.
d NA, not applicable.
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onies (13). The mechanism of colistin resistance of this single
isolate remains unknown.
Twenty positive clinical blood culture sets detected by the
BacT/Alert 3D blood culture system were also tested. Among
them, four were positive with colistin-resistant enterobacterial
isolates in 2 to 4 h of incubation: three isolates belonged to species
that are naturally resistant to colistin (two Serratia marcescens iso-
lates and a single Proteus vulgaris isolate) and a single H. alvei
isolate showed acquired resistance to colistin. The rapid poly-
myxin NP test gave positive results for all of those isolates (Table
1). Sixteen blood cultureswere grownwith enterobacterial isolates
belonging to genera naturally susceptible to colistin (E. coli, Kleb-
siella, Enterobacter, and Citrobacter). None of them presented ac-
quired resistance to colistin (the MICs of colistin ranging from
0.125 to 0.5g/ml) and the rapid polymyxinNP test gave negative
results. Positive blood cultures with nonfermenting bacterial iso-
lates (Acinetobacter spp. andPseudomonas spp.) gave noninterpre-
table results (Fig. 1).
A series of other conditions (variable blood culture dilutions or
conditions of atmosphere incubation) were tested but gave less
optimal results. Indeed, the test performed without blood culture
dilution revealed that the excess of blood prevented the optimal
reading of color changes. We did not observe spontaneous lysis of
the blood cultures that might possibly have interfered with the
results of the test. Other blood culture dilutions (1/5 or 1/100)
gave less rapid positive results (data not shown). Incubation under
CO2 gave false-positive results because of excessive acidification of
the polymyxin NP solution, as opposed to results obtained with
the rapid polymyxin NP test performed with bacterial colonies
(13).
This test performed from blood cultures may have the same
limitation as the rapid polymyxin NP test performed from bacte-
rial colonies (13), i.e., the lack of detection of heteroresistant iso-
lates with lowMICs to polymyxins by BMD. This limitation has to
be further explored.
In conclusion, the rapid polymyxin NP test from positive
blood cultures showed good performances for the detection of
enterobacterial isolates resistant to colistin. It shortens the delay in
obtaining results to ca. 4 h versus 48 h for standard antibiotic
susceptibility testing (24 h for obtaining a bacterial culture and 24
additional hours for susceptibility testing). This test may be im-
plemented for routine testing of blood cultures and is best when
combined with a rapid identification technique such as MALDI-
TOF technology. It is cost-effective since it avoids in particular the
time-consuming steps of manual determination of MIC values
(e.g., powder weighing and dilution). As highlighted above, this
test allows rapid identification of polymyxin-resistant Enterobac-
teriaceae responsible for bacteremia, which is not possible with
molecular techniques, considering the complexity and the diver-
sity of the polymyxin resistance mechanisms.
Early detection of colistin-resistant strains might contribute to
early initiation of appropriate antibiotic therapy for septic pa-
tients infected with multidrug-resistant Enterobacteriaceae. In
countries where carbapenemase-producing enterobacterial iso-
lates are endemic (e.g., Greece and Italy), implementation of the
test might contribute to early initiation of appropriate antibiotic
FIG 1 Strategy for identification of colistin-resistant Enterobacteriaceae from blood cultures using the rapid polymyxin NP test. T, time.
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therapy. Its usemay preserve polymyxin as the last-resort antibio-
therapy. In addition, implementation of contact isolation precau-
tions for carriers of polymyxin-resistant isolates could prevent the
development of outbreaks with thosemultidrug-resistant isolates.
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